1. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV April 24-28, 2013 Amsterdam, The Netherlands Additional Highlights of HCV Investigational Agents and HBV CCO Independent Conference Coverage of the 2013 Annual Meeting of the European Association for the Study of the Liver* This program is supported by an educational grant from *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. This program is supported by educational grants from Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

2. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV About These Slides  Users are encouraged to use these slides in their own noncommercial presentations, but we ask that content and attribution not be changed. Users are asked to honor this intent  These slides may not be published or posted online without permission from Clinical Care Options (email permissions@clinicaloptions.com) Disclaimer The materials published on the Clinical Care Options Web site reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

3. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Faculty Jordan J. Feld, MD, MPH Assistant Professor of Medicine University of Toronto Hepatologist Toronto Western Hospital Liver Centre McLaughlin-Rotman Centre for Global Health Toronto, Ontario, Canada Graham R. Foster, FRCP, PhD Professor of Hepatology The Liver Unit Consultant Hepatologist Queen Marys University of London London, United Kingdom Norah Terrault, MD, MPH Professor of Medicine and Surgery Department of Medicine Division of Gastroenterology University of California, San Francisco San Francisco, California

4. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Faculty Disclosures Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from Achillion, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, Roche, and Vertex; fees for non-CME/CE services received directly from a commercial interest or their agents (e.g., speakers’ bureaus) from AbbVie, Gilead, and Merck; and funds for research support from AbbVie, Gilead Sciences, Roche, and Vertex. Graham R. Foster, FRCP, PhD, has disclosed that he has received consulting fees and fees for non-CME/CE services received directly from a commercial interest or their agents (e.g., speakers’ bureaus) from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Merck, Novartis, and Roche. Norah Terrault, MD, MPH, has disclosed that she has received funds for research support from Abbott, Biotest, Eisai, Genentech, Gilead Sciences, Novartis, Roche, and Vertex and consultant fees from Abbott, Biotest, Bristol-Myers Squibb, Genentech, Gilead Sciences, Merck, Roche, and Siemens.

5. Please review the slide notes for a complete discussion of each study by expert faculty Jordan J. Feld, MD, MPH, Graham R. Foster, FRCP, PhD, and Norah Terrault, MD, MPH.

6. HCV Studies: Prephase III (See accompanying CCO slideset for data on HCV phase III studies and approved agents)

7. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Summary of Investigational HCV Agents Discussed in This Slideset ClassDrugDosingGenotypic Activity NS3/4A protease inhibitorABT-450/RTV 100/100 mg, 150/100 mg, or 200/100 mg QD Genotype 1 NS3 protease inhibitorAsunaprevir200 mg BIDGenotype 1 NS3 protease inhibitorGS-9451200 mg QDGenotype 1 NS3/4A protease inhibitorMK-5172 100 mg, 200 mg, 400 mg, or 800 mg QD Genotype 1 NS3/4A protease inhibitorVaniprevir (MK-7009)300 mg or 600 mg BIDGenotype 1 NS5A nonnucleoside inhibitorABT-26725 mg QDGenotype 1 NS5B nonnucleoside polymerase inhibitorABT-333400 mg BIDGenotype 1 NS5B nonnucleoside polymerase inhibitorBMS-79132575 mg or 150 mg BIDGenotype 1 NS5B nonnucleoside polymerase inhibitorGS-9669500 mg QDGenotype 1 NS5B nucleotide polymerase inhibitorGS-0938300 mg QDGenotypes 1-4 NS5B nucleotide polymerase inhibitorSofosbuvir (GS-7977)400 mg QDPangenotypic NS3/4A protease inhibitorMK-5172 100 mg, 200 mg, 400 mg, or 800 mg QD Genotype 1 NS5A inhibitorLedipasvir (GS-5885)30 mg or 90 mg QDGenotype 1

8. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV QUANTUM: Sofosbuvir ± RBV ± GS-0938 for 12 or 24 Wks in Naive GT 1-4 HCV Pts  Primary endpoint analysis of randomized phase IIb study Lalezari JP, et al. EASL 2013. Abstract 845. Tx-naive pts with GT 1-4 HCV (N = 235) GS-0938 + Sofosbuvir + RBV (n = 25) Wk 12 GS-0938 (n = 27) GS-0938 + Sofosbuvir (n = 25) Sofosbuvir + RBV (n = 25) GS-0938 + Sofosbuvir + RBV (n = 29) Placebo (n = 26) GS-0938 (n = 28) GS-0938 + Sofosbuvir (n = 25) Sofosbuvir + RBV (n = 25) Randomization to available arm Wk 24 GS-0938 dosed at 300 mg QD; sofosbuvir dosed at 400 mg QD. GS-0938 arms halted due to ALT/AST elevations without bilirubin elevations; pts in these arms re-treated with sofosbuvir/RBV for 24 wks

9. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV QUANTUM: Efficacy and Safety of Sofosbuvir + RBV for 12 vs 24 Wks  Apart from ALT/AST elevations with GS-0938, all regimens generally safe and well tolerated –Similar adverse event rates with 12 vs 24 wks for sofosbuvir/RBV –No treatment-related serious adverse events Lalezari JP, et al. EASL 2013. Abstract 845. Virologic Response, n/N (%) Sofosbuvir + RBV 12 Wks (n = 25) Sofosbuvir + RBV 24 Wks (n = 25) RVR25/25 (100) SVR414/25 (56) SVR1214/25 (56)13/25 (52)

10. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV QUANTUM: SVR12 With Sofosbuvir + RBV by Subgroup Subgroup, n/N (%) Sofosbuvir + RBV 12 Wks (n = 25) Sofosbuvir + RBV 24 Wks (n = 25) Younger than 50 yrs of age 50 yrs of age or older 8/10 (80) 6/15 (40) 5/8 (63) 8/17 (47) Black race Nonblack race 2/6 (33) 12/19 (62) 1/3 (33) 12/22 (55) Hispanic Non-Hispanic 2/2 (100) 12/23 (52) 1/2 (50) 12/23 (52) GT 1a GT 1b Non-GT 1 8/15 (53) 2/4 (50) 4/6 (67) 7/15 (47) 2/4 (50) 4/6 (67) Cirrhosis No cirrhosis 0/1 (0) 14/24 (58) 0/2 (0) 13/23 (56) IL28B CC IL28B non-CC 6/6 (100) 8/19 (42) 4/6 (67) 9/19 (47) Lalezari JP, et al. EASL 2013. Abstract 845.

11. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV ELECTRON: Sofosbuvir/RBV ± Ledipasvir or GS-9669 in GT 1 Naive/Null Responders  Nonrandomized phase II study in GT 1 noncirrhotics  AE profile consistent with RBV toxicity profile; 1 pt discontinued due to AE Gane EJ, et al. EASL 2013. Abstract 14. Wk 12 Sofosbuvir + Ledipasvir + RBV Treatment naive (n = 25) Sofosbuvir + Ledipasvir + RBV Sofosbuvir + GS-9669 + RBV Null responders (n = 9) Treatment naive (n = 25) Null responders (n = 10) Sofosbuvir + RBV Treatment naive (n = 25) Sofosbuvir + RBV Null responders (n = 10) Sofosbuvir 400 mg QD; ledipasvir 90 mg QD; GS-9669 500 mg QD; weight-based RBV 1000-1200 mg/day EOT, % SVR4, % SVR12, % 1008884 10010 100 92 100 100* *Only 3 evaluable pts at time of analysis

12. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV AVIATOR: SVR24 With Triple DAA + RBV in GT 1 Naive or Null Responder Pts  Primary endpoint analysis of randomized, open-label phase IIb study Wk 24 Wk 12Wk 8 Cohort 1: treatment-naive GT 1 HCV pts (N = 438) Kowdley KV, et al. EASL 2013. Abstract 3. ABT-450/RTV 150/100 mg QD + ABT-267 + ABT-333 + RBV (n = 80) ABT-450/RTV 150/100 mg QD + ABT-333 + RBV (n = 41) ABT-450/RTV 100/100 mg QD or 200/100 mg QD + ABT-267 + RBV (n = 79) ABT-450/RTV 150/100 mg QD + ABT-267 + ABT-333 (n = 79) ABT-450/RTV 100/100 mg QD or 150/100 mg QD + ABT-267 + ABT-333 + RBV (n = 79) ABT-450/RTV 100/100 mg QD or 150/100 mg QD + ABT-267 + ABT-333 + RBV (n = 80) SVR24, % 88 83 89 87 96 90 ABT-267 dosed at 25 mg QD; ABT-333 dosed at 400 mg BID; weight-based RBV dosed at 1000-1200 mg/day

13. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV AVIATOR: SVR24 With Triple DAA + RBV in GT 1 Naive or Null Responder Pts  Primary endpoint analysis of randomized, open-label phase IIb study Kowdley KV, et al. EASL 2013. Abstract 3. Cohort 2: treatment- experienced GT 1 HCV pts with previous null response (N = 133) ABT-450/RTV 200/100 mg QD + ABT-267 + RBV (n = 45) ABT-450/RTV 100/100 mg QD or 150/100 mg QD + ABT-267 + ABT-333 + RBV (n = 45) ABT-450/RTV 100/100 mg QD or 150/100 mg QD + ABT-267 + ABT-333 + RBV (n = 43) Wk 24Wk 12 SVR24, % 89 93 95 ABT-267 dosed at 25 mg QD; ABT-333 dosed at 400 mg BID; weight-based RBV dosed at 1000-1200 mg/day

14. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV AVIATOR: Subgroup Analyses and Safety Outcomes SVR24 by Baseline Subgroup, % Treatment-Naive Pts Treated for 12 or 24 Wks With ABT-450/RTV + ABT-267 + ABT-333 + RBV (n = 159) Previous Null Responders Treated for 12 or 24 Wks With ABT-450/RTV + ABT-267 + ABT-333 + RBV (n = 88) GT 1a HCV9193 GT 1b HCV9897 IL28B non-CC9594 IL28B CC89100 Kowdley KV, et al. EASL 2013. Abstract 3.  In pooled analysis of 4-drug regimen for 12 or 24 wks, no substantial differences in SVR24 rates in any subgroup  Relapse rates lowest with 4-drug regimen for 12 or 24 wks  Among 247 pts on 4-drug regimen for 12 or 24 wks –Treatment discontinued due to AEs in 6 pts (2.4%) –Serious AEs in 4 pts (1.6%), considered treatment related in 1 pt (arthralgia)

15. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Ledipasvir + GS-9451 + PegIFN/RBV in Tx-Naive Pts With GT 1 HCV, IL28B CC Thompson A, et al. EASL 2013. Abstract 64. Ledipasvir + GS-9451 + PegIFN/RBV* (n = 123) PegIFN/RBV † (n = 121) Tx-naive pts, GT 1 HCV, IL28B CC genotype, noncirrhotic (N = 244) Wk 2 Ledipasvir + GS-9451 + PegIFN/RBV Wk 12Wk 6Wk 24 *92% of pts achieved HCV RNA < LLOQ at Wk 2 and rerandomized to continue quadruple therapy for total of 6 or 12 wks. † 43% of pts achieved HCV RNA < LLOQ at Wk 4 and continued pegIFN/RBV for total of 24 wks.  Interim analysis of randomized, open-label phase II study  3 serious AEs in each arm; AE profile similar between arms SVR12, % 79 98 73 89 } Ledipasvir dosed 30 mg QD; GS-9451 dosed 200 mg QD; pegIFN alfa-2a dosed at 180 µg/wk; RBV dosed at 1000-1200 mg/day.

16. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Ledipasvir + GS-9451 + PegIFN/RBV in Treatment-Experienced GT 1 HCV Pts  Single-arm phase II trial  Ledipasvir 30 mg QD + GS-9451 200 mg QD + pegIFN/RBV for 24 wks –eRVR+: end treatment at Wk 24 –eRVR-: continue pegIFN/RBV alone to Wk 48  Previous treatment response: 44% relapse, 32% null response, 17% partial response, 7% virologic breakthrough  Overall SVR12: 70% –71% of pts achieved eRVR, of whom 87% achieved SVR12  8 SAEs, all attributed to pegIFN/RBV; safety profile similar to pegIFN/RBV Everson GT, et al. EASL 2013. Abstract 13. 100 SVR12 by Subgenotype (%) 80 60 40 20 0 Relapser, Breakthrough Partial Responder Null Responder 100 80 94 52 47 GT 1aGT 1b

17. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Daclatasvir + Asunaprevir + BMS-791325 in Noncirrhotic Tx-Naive GT 1 HCV Pts  Interim analysis of randomized, open-label phase II study  Baseline HCV genotyping: GT 1a (n = 49; 74%), GT 1b (n = 17; 26%)  AE profile similar among arms Everson GT, et al. EASL 2013. Abstract 1423. Noncirrhotic Tx-naive pts with GT 1 HCV (N = 66) Daclatasvir + Asunaprevir + BMS-791325 75 mg BID (n = 16) Daclatasvir + Asunaprevir + BMS-791325 75 mg BID (n = 16) Daclatasvir + Asunaprevir + BMS-791325 150 mg BID (n = 16) Wk 24 Wk 12 Daclatasvir + Asunaprevir + BMS-791325 150 mg BID (n = 18) Response, % EOTSVR4SVR12SVR24SVR36 94 88NA 10094 88 94 NA 9489 NA Daclatasvir dosed at 60 mg QD; aunaprevir dosed at 200 mg BID

18. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Daclatasvir + Sofosbuvir ± RBV in GT 1 Pts With Prior Tx Failure on TVR or BOC  Primary endpoint analysis of randomized, open-label phase IIa study  45% to 48% had TVR/BOC resistance mutations, median 2.4 yrs since previous therapy –No difference in response by absence/presence of resistance mutations  Both regimens well tolerated; 1 serious AE; no discontinuations due to AEs Sulkowski MS, et al. EASL 2013. Abstract 1417. Pts with GT 1 HCV and virologic failure on previous TVR- or BOC-based regimen (N = 41) Daclatasvir 60 mg QD + Sofosbuvir 400 mg QD (n = 21) Daclatasvir 60 mg QD + Sofosbuvir 400 mg QD + RBV 1000-1200 mg/day (n = 20) Wk 24 SVR4, %SVR12, % 100 95

19. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV MK-5172 + PegIFN/RBV in Noncirrhotic Tx-Naive GT 1 HCV Pts  Interim analysis of randomized, double-blind phase II study Manns M, et al. EASL 2013. Abstract 66. Tx-naive pts, noncirrhotic, GT 1 HCV (N = 332) PR Wk 24 Wk 48 Wk 12 Boceprevir + PR † PR Wk 4Wk 36 MK-5172 800 mg QD +PR PR* MK-5172 400 mg QD +PR PR* P/R* MK-5172 200 mg QD +PR PR* MK-5172 100 mg QD + PR PR* Wk 28 *Response-guided therapy: pts with HCV RNA target not detected at Wk 4 received 12 additional wks of PR; pts with detectable HCV RNA (quantifiable or nonquantifiable) at Wk 4 received 36 additional wks of PR. † Response-guided therapy according to approved indication of boceprevir. SVR24,% 86 92 91 87 54

20. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV MK-5172 100 mg QD Selected for Further Studies  Overall efficacy of MK-5172 100 mg QD similar to higher doses –91% of pts receiving MK-5172 100 mg QD eligible for shortened (24-wk) therapy –90% of these pts achieved SVR24  MK-5172 + pegIFN/RBV generally well tolerated  MK-5172 100 mg QD vs BOC + pegIFN/RBV similar rates of SAEs –Early bilirubin increase (> 2 × ULN) similar among doses –Late transaminase increases (> 2 × ULN or > 5 × ULN) Manns M, et al. EASL 2013. Abstract 66.

21. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Vaniprevir + PegIFN/RBV in Cirrhotic, GT 1 HCV, Prior Nonresponders: Tx Arm  Planned subgroup analysis of randomized phase IIb study Rodriguez-Torres M, et al. EASL 2013. Abstract 106. GT 1 HCV pts who failed to respond to pegIFN/RBV subgroup with compensated cirrhosis (N = 74) Vaniprevir 600 mg BID + PegIFN/RBV (n = 14) Vaniprevir 300 mg BID + PegIFN/RBV (n = 15) Vaniprevir 600 mg BID + PegIFN/RBV (n = 15) Vaniprevir 600 mg BID + PegIFN/RBV (n = 16) PegIFN/RBV + Placebo (n = 14) PegIFN/RBV + Placebo Wk 24Wk 48 SVR24,% 68 53 14 Vaniprevir 600 mg BID (pooled) PegIFN alfa-2a dosed at 180 µg/wk; RBV dosed at 1000-1200 mg/day.

22. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Improved SVR24 Rates With Vaniprevir + P/R vs P/R Retreatment 2/ 8 0/ 6 8/ 16 20/ 24 4/ 9 3/ 5 Rodriguez-Torres M, et al. EASL 2013. Abstract 106. Copyright © 2013 Merck Sharp & Dohme Corp, a subsidiary of Merck & Co Inc, Whitehouse Station, NJ, USA. All Rights Reserved. 8/ 42 91/ 117 28/ 41 8/ 15 26/ 39 2/ 14 SVR24 (%) 100 80 60 40 20 0 Vaniprevir 600 mg + PR (Pooled) SVR24 by Cirrhotic GT 1 Subtype Vaniprevir 300 mg + PR Placebo + PR 50 83 44 60 25 GT 1a GT 1b SVR24 (%) 100 80 60 40 20 0 Vaniprevir 600 mg + PR (Pooled) Vaniprevir 300 mg + PR Placebo + PR SVR24 in Cirrhotic vs Noncirrhotic Pts 68 78 53 67 14 19 Cirrhotic Noncirrhotic  Vaniprevir generally well tolerated; increased GI AEs vs control (all mild to moderate)

23. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV COMMAND: 12 or 16 Wks Daclatasvir + PegIFN/RBV in GT 2/3 HCV Pts  Primary endpoint analysis of randomized, placebo-controlled phase II study Dore GJ, et al. EASL 2013. Abstract 1418. Treatment- naive pts, GT 2/3 HCV (N = 151) Daclatasvir + PegIFN/RBV* (n = 50) Daclatasvir + PegIFN/RBV* (n = 50) Placebo + PegIFN/RBV (n = 51) Wk 12Wk 16Wk 24 Daclatasvir 60 mg QD; pegIFN alfa-2a 180 µg/wk; RBV 800 mg/day. *Pts with protocol-defined response (PDR: HCV RNA < 25 IU/mL at Wk 4 and undetectable at Wk 10) received 12 or 16 wks of triple therapy; pts without PDR stopped daclatasvir at Wk 12 and received 12 additional wks of pegIFN/RBV. PegIFN/RBV DCT + P/R GT 2GT 3 8369 8367 6359 SVR24, %

24. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV COMMAND: Response Rates/Safety According to PDR  Similar overall EOT response rates with GT 2 and GT 3; higher relapse with GT 3  Similar proportions (83%) of GT 2 and GT 3 pts met PDR criteria for shortened daclatasvir-based therapy –Among these, 73% of GT 3 and 81% to 94% of GT 2 pts achieved SVR24  AEs, serious AEs with triple therapy generally comparable to pegIFN/RBV alone Dore GJ, et al. EASL 2013. Abstract 1418. PDR: HCV RNA < LLOQ at Wk 4 and < LLOQ TND at Wk 10

25. HBV Studies

26. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV TDF vs TDF/FTC in Patients With High HBV DNA, Normal ALT  Prospective, randomized, double-blind, phase II trial Chan L Y, et al. EASL 2013. Abstract 101. Baseline CharacteristicTDFTDF/FTC Mean age, yrs (SD)33 (9.5)33 (11.2) Asian race, %87.590.3 Mean HBV DNA, log 10 IU/mL (SD) 9.2 (0.4) HBV genotype, %  B  C  Other 51.6 37.5 10.9 51.6 45.2 3.2 Patients with chronic HBV, normal ALT, HBV DNA ≥ 1.7 log 10 IU/mL (N = 126) TDF 300 mg + Placebo (n = 64) Wk 192 TDF 300 mg + FTC 200 mg (n = 62) Primary endpoint: HBV DNA < 69 IU/mL at Wk 192

27. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Efficacy and Safety of TDF vs TDF/FTC in Pts With High HBV DNA, Normal ALT  Higher rate of HBV DNA suppression with TDF/FTC –No significant difference in HBeAg or HBsAg loss  Both regimens well tolerated; no grade 3/4 AEs –No Cr increases > 0.5 mg/dL or CrCL decreases to < 50 mL/min –ALT flare in 1 TDF pt (1.6%), no TDF/FTC pts  No resistance detected in 69 pts who remained viremic Chan L Y, et al. EASL 2013. Abstract 101. Wk 192 Efficacy, % TDF (n = 64) TDF/FTC (n = 62) P Value HBV DNA < 69 IU/mL5576.016 HBeAg loss62.365 HBeAg seroconversion50.244 HBsAg loss/seroconversion00

28. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV REVEAL-HBV: Clearance of HBV DNA, not HBeAg or HBsAg, Reduces Risk of HCC  REVEAL-HBV study cohort (N = 2946; aged 30-65 yrs) –Pts recruited 1991-1992, serum markers evaluated every 6-12 mos until June 30, 2004; HCC rates followed until December 31, 2008  HBV DNA suppression independently associated with significantly reduced risk of HCC –Pts with HBeAg suppression (n = 185) still had high HBV DNA levels and still at high risk of HCC –HBsAg suppression not associated with reduced incidence of HCC, but study not powered to detect difference  Greatest reduction in HCC incidence observed among pts with high baseline HBV DNA (≥ 100,000 copies/mL) who cleared HBV DNA during follow-up –HCC incidence highest in pts HBeAg seropositive throughout follow-up Liu J, et al. EASL 2013. Abstract 40.

29. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV HCC Incidence in TDF Studies Lower Than Predicted by REACH-B Risk Model  Analysis of actual HCC incidence vs REACH-B predictions in 152 cirrhotic, 482 noncirrhotic pts treated with TDF for 8 yrs in studies 102 (HBeAg-) and 103 (HBeAg+)  Noncirrhotics: 8 observed cases vs 18 predicted over 7 yrs –Significant difference from Wk 240: 55% reduction in HCC  Cirrhotics: observed cases matched prediction over first 4 yrs; no observed cases in last 3 yrs  Combined analysis: 50% lower HCC incidence at Yr 7 Kim WR, et al. EASL 2013. Abstract 43.

30. clinicaloptions.com/hepatitis Additional HCV Investigational Agents and HBV Now Take the Test...  To earn CME credit for this activity, please close this window and click the “Test” tab in the CME module underneath.

31. Go Online for More CCO Coverage of EASL 2013! Capsule Summaries of the key studies Additional CME-certified slideset also available for download: HCV Phase III Studies and Approved Agents clinicaloptions.com/amsterdam2013